| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 24,397.0 | 17,601.0 |
| Profit before tax | 8,406.0 | 7,233.0 |
| Net income | 6,451.0 | 5,583.0 |
| EPS (diluted, $ a share) | $7.22 | $6.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +15.5% |
|---|---|
| Revenue, year on year | +38.6% |
10-Q filed with the SEC, NYSE: LLY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
ELI Lilly & Co: key numbers
- Share price
- $1,431.67Close, Nov 16
- Market cap
- $1.35T
- Shares outstanding
- 940.75MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from ELI Lilly & Co
All →ELI Lilly & EVP, GC & Secretary Anat Hakim Sells $7.01M of Stock
Anat Hakim, EVP, GC & Secretary, sold 5,000 shares of ELI Lilly & Co at $1,402.52 a share, worth $7.01M in total on Nov 2, 2026. Shares held after the trade: 4,137 (-54.7%).
- Value
- $7.01M
- Shares
- 5,000
- Price
- $1,402.52
- Role
- EVP, GC & Secretary
- Holding change
- -54.7%
- Trade date
- Nov 2, 2026
ELI Lilly & Financial Results
Eli Lilly reported Q3 2026 revenue of $24.4 billion, a 39% increase driven by strong demand for Mounjaro and Zepbound. The company raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0 to $92.0 billion, reflecting robust global consumer demand and expanded coverage for obesity care.
- Term
- Q3 2026
“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.”
David A. Ricks, Lilly chair and CEO